Satellos Announces Upcoming Oral and Poster Presentations at the 2026 Muscular Dystrophy Association Clinical & Scientific Conference

Key Terms

phase 1a/b medical

Phase 1a/b is an early-stage clinical trial that tests a new drug or medical treatment in people to assess safety, find the right dose, and look for early signs it might work. For investors it matters because positive phase 1a/b results lower scientific and regulatory uncertainty and unlock value by advancing the program to larger trials, while negative results can sharply reduce a treatment’s commercial prospects—similar to passing or failing an initial safety inspection before mass production.

open label medical

Open label is a clinical trial design in which both the participants and the researchers know which treatment or intervention is being given. For investors, this matters because knowledge of the treatment can influence reported effects and side effects—like how seeing a product label can change a shopper’s opinion—so open-label results are useful for safety and real-world experience but are generally viewed as less rigorous evidence of effectiveness than blinded studies.

phase 2 medical

Phase 2 is the mid-stage clinical trial where a new drug or treatment is tested in a larger group of patients to see if it works and to keep checking safety after initial human testing. Think of it as a field test that proves whether a product actually delivers its promised benefit. Investors watch Phase 2 closely because its results strongly influence a medicine’s chances of reaching the market, the size of its potential sales, and the company’s valuation.

pre-funded warrants financial

Pre-funded warrants are financial instruments that give investors the right to purchase a company's stock at a set price, but with most or all of the purchase price paid upfront. They function like a coupon or gift card for stock, allowing investors to buy shares later at a fixed price, which can be beneficial if they want to avoid future price increases. This makes them important for investors seeking flexibility and certainty in their investment plans.

underwritten public offering financial

An underwritten public offering is when a company sells new shares of its stock to the public with the help of a financial firm, called an underwriter. The underwriter agrees to buy all the shares upfront, reducing the company's risk, and then sells them to investors. This process helps companies raise money quickly and confidently from a wide range of buyers.

placebo-controlled medical

"Placebo-controlled" describes a testing method where one group receives the actual treatment or intervention, while another group receives a harmless, inactive version called a placebo. This approach helps determine whether the real treatment has genuine effects beyond psychological expectations. For investors, understanding this ensures confidence that reported benefits are real and not influenced by bias or false perceptions.

double-blind medical

A double-blind process means that neither the people conducting an activity nor the people involved know certain key details, such as who is receiving a treatment or a placebo. This approach helps prevent bias from influencing the results, making the outcome more trustworthy. For investors, it ensures that decisions or judgments are based on unbiased information rather than preconceived opinions or expectations.

clinical trial medical

A clinical trial is a carefully controlled study in which a new medicine, medical device, or treatment is tested on people to see if it is safe and effective. For investors it matters because trial results determine whether a product can win regulatory approval and reach patients, much like a road test decides if a new car can be sold; positive or negative results can sharply change a company’s prospects and stock value.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

TORONTO--(BUSINESS WIRE)-- Satellos Bioscience Inc. (Nasdaq: MSLE, TSX: MSCL) (“Satellos” or the “Company”), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle diseases, today announced that it will present two oral scientific presentations and three posters at the 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference, taking place March 8-11 in Orlando, Florida.

Oral presentations feature data from the completed Phase 1a/b study of SAT-3247 in healthy volunteers and adult patients with Duchenne muscular dystrophy (DMD), as well as new preclinical data evaluating the impact of SAT-3247 in a mouse model of facioscapulohumeral muscular dystrophy (FSHD).

Oral Presentations:

• Abstract Title: Assessing the impact of SAT-3247 on muscle force in a mouse model of FSHD
• Presenter: Phil Lambert, PhD, Satellos Chief Scientific Officer
• Time: Wednesday, Mar. 11, 9:30 – 9:45 a.m. ET
• Session: Novel Therapeutics Approaches
• Location: Florida 1-3
  

• Abstract Title: A Phase 1a/b open label study of SAT-3247 in healthy volunteers and adult patients with Duchenne Muscular Dystrophy (Poster #394 O)
• Presenter: Wildon Farwell, MD, MPH, Satellos Chief Medical Officer
• Time: Wednesday, Mar. 11, 11:30 – 11:45 a.m. ET
• Session: Clinical Trial Updates
• Location: Florida 4

Poster Presentations:

Posters sessions will take place from 10:30 a.m. – 1:30 p.m., 4 – 4:30 p.m., 6 – 8 p.m. on Tuesday, March 10 in the conference exhibit hall.

• Title: A Phase 1a/b open label study of SAT-3247 in healthy volunteers and adult patients with Duchenne Muscular Dystrophy
• Presenter: Wildon Farwell, MD, Satellos Chief Medical Officer
• Poster Number: 394 O
  

• Title: TRAILHEAD: An Open-Label, Phase 2 Study Evaluating Long-Term Safety and Efficacy of SAT-3247 in Adults with Duchenne Muscular Dystrophy (DMD)
• Presenter: Kristiana Salmon, Satellos Clinical Scientist
• Poster Number: 487 LB
  

• Title: Regenerative Index Quantitation Reveals a Reduced Regenerative Potential in Duchenne Muscular Dystrophy from 7-11 years of age
• Presenter: Ryan Mitchell, PhD, Satellos Senior VP, Head of Corporate Development
• Poster Number: 282 T

Full details from the scientific presentations and posters will follow in a future press release and will be available on the Events and Presentations page of the Satellos website.

For more information on the 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference, visit https://www.mdaconference.org/.

ABOUT SAT-3247

SAT-3247 is a proprietary, oral, small molecule drug being developed by Satellos as a novel treatment to regenerate skeletal muscle that is lost in Duchenne and other degenerative or injury conditions. Satellos is advancing SAT-3247 as a potential treatment for DMD, independent of dystrophin and regardless of exon mutation status.

ABOUT SATELLOS BIOSCIENCE INC.

Satellos is a clinical-stage drug development company focused on restoring natural muscle repair and regeneration in degenerative muscle diseases. Through its research, Satellos has developed SAT-3247, a first-of-its-kind, orally administered small molecule drug designed to address deficits in muscle repair and regeneration. SAT-3247 targets AAK1, a key protein that Satellos has identified as capable of helping restore muscle stem cell signaling that is disrupted in DMD. By addressing the loss of dystrophin-dependent cues, SAT-3247 may re-establish the signals that support effective muscle regeneration. SAT-3247 is currently in clinical development as a potential disease-modifying treatment, initially for DMD. Satellos is also working to identify additional muscle diseases or injury conditions where restoring muscle repair and regeneration may have therapeutic benefit and represent future clinical development opportunities. For more information, visit www.satellos.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260224750319/en/

Investors: Liz Williams, CFO, ir@satellos.com
Media: Emily Williams, Senior Director of Communications, media@satellos.com

Source: Satellos Bioscience Inc.